Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Intra- and interindividual variation in drug responses is one major reason for the failure of drug therapy, drug toxicity, and even the death of patients. Precision medicine, or personalized medicine, is a field of medicine that customizes an individual's medical diagnosis and treatment based on his/her genes, microbiomes, environments, etc. Over the past decade, a large number of studies have demonstrated that gut microbiota can modify the efficacy and toxicity of drugs, and the extent of the modification varies greatly from person to person because of the variability of the gut microbiota. Personalized manipulation of gut microbiota is an important approach to rectify the abnormal drug response. In this review, we aim to improve drug efficacy and reduce drug toxicity by combining precision medicine and gut microbiota. After describing the interactions between gut microbiota and xenobiotics, we discuss (1) the effects of gut microbiota on drug efficacy and toxicity and the corresponding mechanisms, (2) the variability of gut microbiota, which leads to variation in drug responses, (3) the biomarkers used for the patient stratification and treatment decisions before the use of drugs, and (4) the methods used for the personalized manipulation of gut microbiota to improve drug outcomes. Overall, we hope to improve the drug response by incorporating the knowledge of gut microbiota into clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · cited 1×
“The contents of these metabolites such as SCFAs and choline have been demonstrated to vary greatly in different people [105,106].”
BackgroundGut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 3×
“muciniphila and other bacteria can serve as biomarkers for predicting the outcomes of PD-1 blockade in patients with epithelial tumors and metastatic melanoma [86,88,131].”
BackgroundHost-gut microbiota metabolic interactions
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760 · cited 3×
“Gut microbiota can synthesize and release a large group of metabolites such as SCFAs, secondary bile acids, choline metabolites, and lipids [28,29].”
BackgroundThe Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637 · cited 1×
“The functions of gut microbiota include but are not limited to the metabolism of xenobiotics, biosynthesis of vitamins, steroid hormones, and neurotransmitters, modulation of host immune maturation, cell proliferation, vascularization and neurologic signaling [99].”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“fragilis were responsible for the efficacy of CTLA-4 blockade [134].”
BackgroundThe commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 1×
“muciniphila and other bacteria can serve as biomarkers for predicting the outcomes of PD-1 blockade in patients with epithelial tumors and metastatic melanoma [86,88,131].”
BackgroundEnvironment dominates over host genetics in shaping human gut microbiota
Rothschild, D., Weissbrod, O., Barkan, E., Kurilshikov, A., Korem, T., Zeevi, D., Costea, P. I., Godneva, A., Kalka, I. N., Bar, N., et al. (2018) · Nature · doi:10.1038/nature25973 · Cited by 2,859 · cited 1×
“composition of gut microbiota [93], although there is controversy regarding which factor plays a more significant role [94,95].”
BackgroundMicrobiota and SCFA in lean and overweight healthy subjects
Schwiertz, A., Taras, D., Schäfer, K., Beijer, S., Bos, N. A., Donus, C., & Hardt, P. D. (2010) · Obesity · doi:10.1038/oby.2009.167 · Cited by 2,457
Factors influencing the composition of the intestinal microbiota in early infancy
Penders, J., Thijs, C., Vink, C., Stelma, F. F., Snijders, B., Kummeling, I., van den Brandt, P. A., & Stobberingh, E. E. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2824 · Cited by 2,232
Probiotics and prebiotics in intestinal health and disease: from biology to the clinic
Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0173-3 · Cited by 2,059
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Self-citationChaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Paramsothy, S., Kamm, M. A., Kaakoush, N. O., Walsh, A. J., van den Bogaerde, J., Samuel, D., Leong, R. W. L., Connor, S., Ng, W., Paramsothy, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30182-4 · Cited by 1,276 · cited 1×
“Clinical studies have shown that this method is a promising therapeutic option to treat diseases such as Clostridioides difficile infection and ulcerative colitis [170,171], although the feasibility, efficacy and safety of this approach need to be studied further [172,173].”
BackgroundMapping human microbiome drug metabolism by gut bacteria and their genes
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160
Probiotics, gut microbiota, and their influence on host health and disease
Sánchez, B., Delgado, S., Blanco‐Míguez, A., Lourenço, A., Gueimonde, M., & Margolles, A. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600240 · Cited by 1,104
Diet dominates host genotype in shaping the murine gut microbiota
Carmody, R. N., Gerber, G. K., Luevano, J. M., Gatti, D. M., Somes, L., Svenson, K. L., & Turnbaugh, P. J. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2014.11.010 · Cited by 1,103 · cited 1×
“It has been shown that the diet can rapidly and profoundly change gut microbiota and can also influence the interindividual variation of host microbial communities [180].”
BackgroundChemical transformation of xenobiotics by the human gut microbiota
Koppel, N., Maini Rekdal, V., & Balskus, E. P. (2017) · Science · doi:10.1126/science.aag2770 · Cited by 1,080 · cited 3×
“This can be explained by the fact that gut microbiota enzymes primarily catalyze hydrolytic and reductive reactions while liver enzymes typically perform oxidative and conjugative reactions [9].”
BackgroundSegata, N., Haake, S. K., Mannon, P., Lemon, K. P., Waldron, L., Gevers, D., Huttenhower, C., & Izard, J. (2012) · Genome Biology · doi:10.1186/gb-2012-13-6-r42 · Cited by 1,076
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 1×
“found out that a higher abundance of Bacteroidetes is correlated with ipilimumab-induced colitis in humans [133].”
BackgroundExploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials
Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A., & Marraffini, L. A. (2014) · Nature Biotechnology · doi:10.1038/nbt.3043 · Cited by 986
Microbiota Diurnal Rhythmicity Programs Host Transcriptome Oscillations
Thaiss, C. A., Levy, M., Korem, T., Dohnalová, L., Shapiro, H., Jaitin, D. A., David, E., Winter, D. R., Gury-BenAri, M., Tatirovsky, E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.003 · Cited by 870 · cited 2×
“Disruption of the normal gut microbiota rhythm induces genetic fluctuations in the intestine and liver, and hence gut microbiota can impact hepatic drug detoxification and hepatotoxicity [111].”
BackgroundSequence-specific antimicrobials using efficiently delivered RNA-guided nucleases
Citorik, R. J., Mimee, M., & Lu, T. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.3011 · Cited by 808 · cited 1×
“For example, with the help of the clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 system, RNA-guided nucleases targeting specific DNA sequences can be efficiently delivered to microbial populations by phages [203].”
BackgroundImpact of commonly used drugs on the composition and metabolic function of the gut microbiota
Vich Vila, A., Collij, V., Sanna, S., Sinha, T., Imhann, F., Bourgonje, A. R., Mujagic, Z., Jonkers, D. M. A. E., Masclee, A. A. M., Fu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14177-z · Cited by 791
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740 · cited 1×
“A recent clinical study showed that FMT can rapidly and significantly ameliorate colitis caused by immune checkpoint inhibitors [178], exemplifying the use of FMT to reduce the toxicity of drugs.”
BackgroundPredicting and Manipulating Cardiac Drug Inactivation by the Human Gut Bacterium Eggerthella lenta
Haiser, H. J., Gootenberg, D. B., Chatman, K., Sirasani, G., Balskus, E. P., & Turnbaugh, P. J. (2013) · Science · doi:10.1126/science.1235872 · Cited by 704
Human Sulfotransferases and Their Role in Chemical Metabolism
Gamage, N., Barnett, A., Hempel, N., Duggleby, R. G., Windmill, K. F., Martin, J. L., & McManus, M. E. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj061 · Cited by 703 · cited 1×
“In the liver, p-cresol is metabolized to p-cresol sulfate, a substrate of the human cytosolic sulfotransferase 1A1 (SULT1A1), which is shared by acetaminophen [76].”
BackgroundOtt, S. J., Waetzig, G. H., Rehman, A., Moltzau-Anderson, J., Bharti, R., Grasis, J. A., Cassidy, L., Tholey, A., Fickenscher, H., Seegert, D., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.010 · Cited by 695 · cited 1×
“difficile infection (although in this case the metabolites may also contribute to the efficacy of treatment) [202], and the other is to confer stronger and more specific bacteria-killing effects by engineering the phages.”
BackgroundFord, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619
The gastrointestinal microbiota as a site for the biotransformation of drugs
Sousa, T., Paterson, R., Moore, V., Carlsson, A., Abrahamsson, B., & Basit, A. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.009 · Cited by 618 · cited 1×
“The typical difference between liver metabolism and gut microbiota metabolism is that liver metabolism usually increases the molecular polarity and molecular weight of xenobiotics while the other one usually decreases the molecular polarity and molecular weight of xenobiotics [18].”
BackgroundEffects of antibiotics on gut microbiota
Lange, K., Buerger, M., Stallmach, A., & Bruns, T. (2016) · Digestive Diseases · doi:10.1159/000443360 · Cited by 607 · cited 1×
“For example, traditional antibiotics often cause long-term and widespread destruction of the gut microbiota composition and even lead to antibiotic resistance, which may further promote the development and aggravation of diseases [216].”
BackgroundIsabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4222 · Cited by 605 · cited 2×
“coli Nissle with the ability to express genes encoding phenylalanine-metabolizing enzymes [205].”
BackgroundDynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model
Hsu, B. B., Gibson, T. E., Yeliseyev, V., Liu, Q., Lyon, L., Bry, L., Silver, P. A., & Gerber, G. K. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.05.001 · Cited by 573 · cited 1×
“However, evidence has supported the utilization of phages to modulate the gut microbiota composition [200,201].”
BackgroundZheng, Y., Wang, T., Tu, X., Huang, Y., Zhang, H., Tan, D., Jiang, W., Cai, S., Zhao, P., Song, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0650-9 · Cited by 550
Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319548 · Cited by 506
Trimethylamine N-oxide: the good, the bad and the unknown.
Velasquez, M., Ramezani, A., Manal, A., & Raj, D. (2016) · Toxins · doi:10.3390/toxins8110326 · Cited by 504
Engineering bacteria for diagnostic and therapeutic applications
Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460 · cited 2×
“Currently, microbiome engineering is an exciting and promising approach that can be used for diagnostic and therapeutic applications [198].”
BackgroundLan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., & Sun, G. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.09.049 · Cited by 458 · cited 1×
“However, the use of a large dose of berberine in the clinic can also induce diarrhea, constipation, abdominal distension and abdominal pain [119,120].”
BackgroundAnanthakrishnan, A. N., Luo, C., Yajnik, V., Khalili, H., Garber, J. J., Stevens, B. W., Cleland, T., & Xavier, R. J. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.04.010 · Cited by 451 · cited 1×
“For example, vedoNet, a neural network algorithm that incorporates the gut microbiota and clinical data, can predict patients’ response to inflammatory bowel disease treatment [150].”
BackgroundTHE ROLE OF INTESTINAL BACTERIA IN THE METABOLISM OF SALICYLAZOSULFAPYRIDINE
PEPPERCORN, M. A., & GOLDMAN, P. (1972) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29238-2 · Cited by 450
Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation
Riglar, D. T., Giessen, T. W., Baym, M., Kerns, S. J., Niederhuber, M. J., Bronson, R. T., Kotula, J. W., Gerber, G. K., Way, J. C., & Silver, P. A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3879 · Cited by 426 · cited 1×
“In contrast, the engineered diagnostic bacteria can function either directly within the body or indirectly in ex vivo clinical samples [196,197].”
BackgroundInactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423 · cited 1×
“In approximately 10% of patients, a substantial amount of digoxin is converted into dihydrodigoxin, a cardio-inactive product [38].”
BackgroundKurtz, C. B., Millet, Y. A., Puurunen, M. K., Perreault, M., Charbonneau, M. R., Isabella, V. M., Kotula, J. W., Antipov, E., Dagon, Y., Denney, W. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7975 · Cited by 399
Dunn, C. J., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549050-00007 · Cited by 391
Probiotics, prebiotics and amelioration of diseases
Tsai, Y.-L., Lin, T.-L., Chang, C.-J., Wu, T.-R., Lai, W.-F., Lu, C.-C., & Lai, H.-C. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-018-0493-6 · Cited by 388
Mimee, M., Tucker, A. C., Voigt, C. A., & Lu, T. K. (2015) · Cell Systems · doi:10.1016/j.cels.2015.06.001 · Cited by 387
Gnotobiotic mouse model of phage–bacterial host dynamics in the human gut
Reyes, A., Wu, M., McNulty, N. P., Rohwer, F. L., & Gordon, J. I. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319470110 · Cited by 355 · cited 1×
“However, evidence has supported the utilization of phages to modulate the gut microbiota composition [200,201].”
BackgroundMüller, M., Canfora, E., & Blaak, E. (2018) · Nutrients · doi:10.3390/nu10030275 · Cited by 329 · cited 1×
“Xenobiotics such as insoluble fibers can influence the intestinal transit time and thus indirectly change the composition of gut microbiota [24].”
BackgroundLi, L., Ning, Z., Zhang, X., Mayne, J., Cheng, K., Stintzi, A., & Figeys, D. (2020) · Microbiome · doi:10.1186/s40168-020-00806-z · Cited by 328
Buse, J. B., DeFronzo, R. A., Rosenstock, J., Kim, T., Burns, C., Skare, S., Baron, A., & Fineman, M. (2016) · Diabetes Care · doi:10.2337/dc15-0488 · Cited by 325 · cited 1×
“In addition, the delayed release formulation of metformin showed blood glucose-lowering effects comparable to those of the standard formulation, even though the systemic level of metformin was significantly reduced [48].”
BackgroundGut reactions: Breaking down xenobiotic–microbiome interactions
Clarke, G., Sandhu, K. V., Griffin, B. T., Dinan, T. G., Cryan, J. F., & Hyland, N. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015768 · Cited by 319 · cited 2×
“On the one hand, drugs can compositionally and functionally change gut microbiota; on the other hand, gut microbiota can chemically transform drugs [10].”
BackgroundA Review of Acetaminophen Poisoning
Hodgman, M. J., & Garrard, A. R. (2012) · Critical Care Clinics · doi:10.1016/j.ccc.2012.07.006 · Cited by 314
Transforming berberine into its intestine-absorbable form by the gut microbiota
Feng, R., Shou, J.-W., Zhao, Z.-X., He, C.-Y., Ma, C., Huang, M., Fu, J., Tan, X.-S., Li, X.-Y., Wen, B.-Y., et al. (2015) · Scientific Reports · doi:10.1038/srep12155 · Cited by 307 · cited 1×
“A recent study showed that nitroreductases, a group of enzymes from gut microbiota with the capability to catalyze the reductive reaction of drugs bearing nitroheterocyclic and nitroaromatic structures, convert berberine into the absorbable compound dihydroberberine and thus significantly improve the bioavailability o…”
BackgroundAn atlas of β-glucuronidases in the human intestinal microbiome
Pollet, R. M., D'Agostino, E. H., Walton, W. G., Xu, Y., Little, M. S., Biernat, K. A., Pellock, S. J., Patterson, L. M., Creekmore, B. C., Isenberg, H. N., et al. (2017) · Structure · doi:10.1016/j.str.2017.05.003 · Cited by 289
Slyepchenko, A., Maes, M., Jacka, F. N., Köhler, C. A., Barichello, T., McIntyre, R. S., Berk, M., Grande, I., Foster, J. A., Vieta, E., et al. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448957 · Cited by 278
Circadian rhythm and the gut microbiome
Voigt, R. M., Forsyth, C. B., Green, S. J., Engen, P. A., & Keshavarzian, A. (2016) · International Review of Neurobiology · doi:10.1016/bs.irn.2016.07.002 · Cited by 274
Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics
Carmody, R. N., & Turnbaugh, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72335 · Cited by 268 · cited 1×
“When entering the gastrointestinal tract, orally administered drugs inevitably interact with gut microbiota [8,9].”
BackgroundMcFarland, L. V. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005047 · Cited by 235
Resistance and intolerance to statins
Reiner, Ž. (2014) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.009 · Cited by 225 · cited 1×
“It has been reported that some patients are statin-resistant while others are statin-intolerant [51].”
BackgroundEnteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment
Kaddurah-Daouk, R., Baillie, R. A., Zhu, H., Zeng, Z.-B., Wiest, M. M., Nguyen, U. T., Wojnoonski, K., Watkins, S. M., Trupp, M., & Krauss, R. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025482 · Cited by 193
Saitta, K. S., Zhang, C., Lee, K. K., Fujimoto, K., Redinbo, M. R., & Boelsterli, U. A. (2014) · Xenobiotica · doi:10.3109/00498254.2013.811314 · Cited by 165 · cited 6×
“β-glucuronidases also play a similar role in the toxic effects of NSAIDs [58].”
BackgroundInfluentialGut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?
Quigley, E. M. M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.29 · Cited by 125
Nakayama, H., Kinouchi, T., Kataoka, K., Akimoto, S., Matsuda, Y., & Ohnishi, Y. (1997) · Pharmacogenetics · doi:10.1097/00008571-199702000-00005 · Cited by 120 · cited 1×
“Thus, combined administration of sorivudine and 5-FU, increases the circulating 5-FU levels, leading to 5-FU-associated death [79,80].”
BackgroundMolecular aspects of circadian pharmacology and relevance for cancer chronotherapy
Ozturk, N., Ozturk, D., Kavakli, I. H., & Okyar, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102168 · Cited by 106 · cited 1×
“The circadian rhythm is an important factor that can impact not only the physiological function of mammals including immune responses, apoptosis, cell proliferation and differentiation, but also the efficacy and toxicity of drugs [109].”
BackgroundThe degradative pathway of the s-triazine melamine. The steps to ring cleavage
Jutzi, K., Cook, A. M., & Hütter, R. (1982) · Biochemical Journal · doi:10.1042/bj2080679 · Cited by 101 · cited 1×
“In the food safety field, animal studies have demonstrated that the combination of melamine and broad-spectrum antibiotics can significantly reduce kidney injury caused by melamine [165], and the mechanism is associated with the reduced transformation of melamine into cyanuric acid by gut microbiota [166,167].”
BackgroundMetabolism of Melamine by Klebsiella terragena
Shelton, D. R., Karns, J. S., McCarty, G. W., & Durham, D. R. (1997) · Applied and Environmental Microbiology · doi:10.1128/aem.63.7.2832-2835.1997 · Cited by 87
Digoxin Metabolism in Patients
Peters, U. (1978) · Archives of Internal Medicine · doi:10.1001/archinte.1978.03630320018009 · Cited by 84 · cited 1×
“The conversion of digoxin by gut microbiota in patients can account for the inactivation of more than 50% of the administered digoxin [39], which significantly influences the bioavailability and clinical toxicity of this drug.”
BackgroundMathan, V. I., Wiederman, J., Dobkin, J. F., & Lindenbaum, J. (1989) · Gut · doi:10.1136/gut.30.7.971 · Cited by 62
Cited by
Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives
Liu, J., Tan, Y., Cheng, H., Zhang, D., Feng, W., & Peng, C. (2022) · Aging and disease · doi:10.14336/ad.2022.0104 · Cited by 529
“such as metformin, berberine, aconitine [4].”
BackgroundSelf-citationOscillospira - a candidate for the next-generation probiotics
Yang, J., Li, Y., Wen, Z., Liu, W., Meng, L., & Huang, H. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1987783 · Cited by 471
The interaction among gut microbes, the intestinal barrier and short chain fatty acids
Ma, J., Piao, X., Mahfuz, S., Long, S., & Wang, J. (2022) · Animal Nutrition · doi:10.1016/j.aninu.2021.09.012 · Cited by 398
The mechanism of berberine alleviating metabolic disorder based on gut microbiome
Wang, H., Zhang, H., Gao, Z., Zhang, Q., & Gu, C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.854885 · Cited by 69
“, 2017; Greenhill, 2018; Guerre, 2020; Philippe, 2020), and at the same time, the gut microbiota can be mediated by drugs that regulate the body’s metabolism and play a role in improving metabolic disorders (Feng et al., 2020).”
BackgroundLadeira, R., Tap, J., & Derrien, M. (2023) · Microbiome Research Reports · doi:10.20517/mrr.2023.01 · Cited by 19
Metadata
- Authors
- Feng, W., Liu, J., Ao, H., Yue, S., & Peng, C.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 10
- Issue
- 24
- Pages
- 11278-11301
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3087840193
- Cited by
- 121
- References
- 69
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.